355
356
357
358
33. Zhang, Y-K.; Plattner, J. J.; Freund, Y. R.; Easom, E. E.; Zhou, Y.;
Gut, J.; Rosenthal, P. J.; Waterson, D.; Gamo, F-J.; Angulo-
Barturen, I.; Ge, M.; Li, Z.; Li. L.; Jian, Y.; Cui, H.; Wang, H.;
Yang, J.; Bioorg. Med. Chem. Lett. 2011, 21, 644-651.
34. Jacobs, R. T.; Plattner, J. J.; Nare, B.; Wring, S. A.; Chen, D.;
Freund, Y.; Gaukel, E. G.; Orr, M. D.; Perales, J. B.; Jenks, M.;
Noe, R. A.; Sligar, J. M.; Zhang, Y.-K.; Bacchi, C. J.; Yarlett, N.;
Don, R. Future Med. Chem. 2011, 3, 1259-1278.
35. Ding, D.; Meng, Q.; Gao, G.; Zhao, Y.; Wang, Q.; Nare, B.; Jacobs,
R.; Rock, F.; Alley, M. R. K.; Plattner, J. J.; Chen, G.; Li, D.; Zhou,
H. J. Med. Chem. 2011, 54, 1276-1287.
36. Alam, M. A.; Arora, K.; Gurrapu, S.; Jonnalagadda, S. K.; Nelson,
G. L.; Kiprof, P.; Jonnalagadda, S. C.; Mereddy, V. R. Tetrahedron.
2016, 72, 3795-3801.
37. Kumar, J. S.; Alam, M. A.; Gurrapu, S.; Nelson, G. L.; Williams,
M.; Corsello, M. A.; Johnson, J. L.; Jonnalagadda, S. C.; Mereddy.
V. R. J. Het. Chem. 2013, 50, 814-820.
38. Kumar, J. S.; Bashian, C. M.; Corsello, M. A.; Jonnalagadda, S. C.;
Mereddy, V. R. Tetrahedron Lett. 2010, 51, 4482-4485.
39. Kumar, J. S.; Jonnalagadda, S. C.; Mereddy, V. R. Tetrahedron
Lett. 2010, 51, 779-782.
40. Gunasekera, D. S.; Gerold, D. A.; Aalderks, N. A.; Jonnalagadda,
S. C.; Kiprof, P.; Zhdankin, V. V.; Reddy, M. V. R. Tetrahedron
2007, 63, 9401-9405.
41. Lennarz, W. J.; Snyder, H. R., J. Am. Chem. Soc. 1960, 82, 2172-
2175.
279 References and notes
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
1.
2.
Hanahan, D. & Weinberg, R. A. Cell, 2011, 144, 646–674.
Hamanaka, R. B. & Chandel, N. S. J. Exp. Med. 2012, 209, 211–
359
360
215.
Granchi, C.; Fancelli, D.; Minutolo, F. Bioorg. Med. Chem. Lett.
3.
4.
361
362
2014, 24, 4915–4925.
Annibaldi, A. & Widmann, C. Curr. Opin. Clin. Nutr. Metab. Care
363
364
2010, 13, 466–470.
Weinberg, S. E. & Chandel, N. S. Nat. Chem. Biol. 2014, 11, 9–15.
5.
6.
365
Sotgia, F.; Whitaker-Menezes, D.; Martinez-Outschoorn, U. E.;
366
Salem, A. F.; Tsirigos, A.; Lamb, R.; Sneddon, S.; Hulit, J.; Howell,
367
368
A.; Lisanti, M. P. Cell Cycle 2012, 11, 4390–4401.
Martinez-Outschoorn, U. E.; Lin, Z.; Whitaker-Menezes, D.;
7.
369
Howell, A.; Lisanti, M. P.; Sotgia, F. Cell Cycle 2012, 11, 3956–
370
371
63.
Salem, A. F.; Whitaker-Menezes, D.; Howell, A.; Sotgia, F.;
8.
9.
372
373
Lisanti, M. P. Cell Cycle. 2012, 11, 4174-80.
Simões, R. V.; Serganova, I. S.; Kruchevsky, N.; Leftin, A.;
374
Shestov, A. A.; Thaler, H. T.; Sukenick, G.; Locasale, J. W.;
375
Blasberg, R. G.; Koutcher, J. A.; Ackerstaff, E. Neoplasia 2015, 17,
376
377
671–684.
10. Yan, B.; Dong, L. and Neuzil, J. Mitochondrion 2016, 26, 86–93.
378
11. Kim, H. K.; Noh, Y. H.; Nilius, B.; Ko, K. S.; Rhee, B. D.; Kim,
379
380
N.; Han, J. Semin Cancer Biol, 2017, 47, 154-167.
12. Jia, D.; Park, J. H.; Jung, K. H.; Levine, H.; Kaipparettu, B. A.
381
382
42. Alexander, C.; Smith, C. R.; Whitcombe, M. J.; Vulfson, E. N., J.
Am. Chem. Soc., 1999, 121, 6640-6651.
Cells. 2018, 7, pii: E21.
13. Corbet, C. and Feron, O. Biochim Biophys Acta Rev Cancer. 2017,
383
384
43. Materials: 2-formyl phenylboronic acid (AKSci), sodium
borohydride (AKSci), fuming nitric acid (Alfa-Aesar), 10% Pd-C
(Sigma-Aldrich), ammonium formate (AKSci), aryl phosphoniums
(AKSci), were purchased from commercial sources. All other
chemicals were of reagent grade quality and purchased from Sigma-
1868, 7-15.
14. Deus, C. M.; Santos, G. L.; Loureiro, R.; Vega-Naredo, I.; Faneca,
385
386
H.; Oliveira, P. J. Curr. Med. Chem. 2015, 22, 2438–57.
15. Dong, L. F.; Jameson, V. J.; Tilly, D.; Cerny, J.; Mahdavian, E.;
387
Marín-Hernández, A.; Hernández-Esquivel, L.; Rodríguez-
1
388
Aldrich. The H- and 13C-NMR spectra were plotted on a Varian
Enríquez, S.; Stursa, J.; Witting, P. K.; Stantic, B.; Rohlena, J.;
389
Oxford-500 spectrometer. High-resolution mass spectra (HRMS)
were recorded using a Bruker BioTOF II ESI mass spectrometer.
Elemental analysis (CHN) results were obtained from Atlantic
Microlab services.
Truksa, J.; Kluckova, K.; Dyason, J. C.; Ledvina, M.; Salvatore, B.
390
A.; Moreno-Sánchez, R.; Coster, M. J.; Ralph, S. J.; Smith, R. A.;
391
392
Neuzil, J. J. Biol. Chem. 2011, 286, 3717–28.
16. Zielonka, J.; Joseph, J.; Sikora, A.; Hardy, M.; Ouari, O.; Vasquez-
393
44. Cell culture conditions and cytotoxicity: 4T1 cells (ATCC): RPMI-
1640 supplemented with 10% FBS and penicillin-streptomycin
(50U/ml, 50µg/ml). MCF7 cells (ATCC): α-MEM (500 mL)
supplemented with EGF (6.25 μg), hydrocortisone (0.5 mg), non-
essential amino acids (1%), insulin (0.5 mg), HEPES (10 mM),
sodium pyruvate (1 mM), and 30 mL FBS. MIA PaCa-2 cells
(ATCC): DMEM supplemented with 10% FBS, 2.5% horse serum,
and penicillin-streptomycin (50U/ml, 50µg/ml). WiDr cells
(ATCC): MEM supplemented with 10% FBS and penicillin-
streptomycin (50U/ml, 50µg/ml). Cancer cells were seeded in 96-
well plate at a density of 5x103 cells/well and incubated for 18-24
hours. Test compounds were added into the wells at various
concentrations and incubated for further 72 hours. 10 μL of MTT
(5 mg in 1 mL of 1X PBS) was added into the wells and incubated
for 4 hours followed by the addition of 100 μL of 10% SDS in
0.01N HCl was added to quench the reaction. The plates were
further incubated for 4 hours and the absorbance was recorded at
570 nm using BioTek Synergy 2 SLFA microplate reader. IC50 was
calculated using Graphpad Prism software by plotting absorbance
on y-axis and log[C] on x-axis.
Vivar, J.; Cheng, G.; Lopez, M.; Kalyanaraman, B. Chem. Rev.
394
395
2017, 117, 10043–10120.
17. Millard, M.; Gallagher, J. D.; Olenyuk, B. Z.; Neamati, N. J. Med.
396
Chem. 2013, 56, 9170–9179.
397
398
18. Zielonka, J.; Joseph, J.; Sikora, A.; Hardy, M.; Ouari, O.;
Vasquez-Vivar, J.; Cheng, G.; Lopez, M.; Kalyanaraman, B.; ACS
399
Chem. Rev. 2017, 117, 10043−10120.
400
401
402
19. Asin-Cayuela, J.; Manas, AB.; James, A.M.; Smith, R.A.;
Murphy, M.P.; FEBS Lett. 2004, 28597, 9-16.
20. Ross, M.F.; Prime, T.A., Abakumova, I.; James, A.M.; Porteous,
403
C.M.; Smith, R.A.J.; Murphy, M.P.; Biochem. J. 2008, 411 633–
404
645.
405
406
407
21. Ross, M.F.; Flipovska, A.; Smith, R.A.J.; Gait, M.J.; Murphy,
M.P.; Biochem. J. 2004, 303, 457-468.
22. Kramar, R.; Hohenegger, M.; Srour, A. N.; Khanakah, G. Agents
408
Actions 1984, 15, 660–3.
23. Cannon, J. R.; Tapias, V.; Na, H. M.; Honick, A. S.; Drolet, R. E.;
409
410
Greenamyre, J. T. Neurobiol. Dis. 2009, 34, 279–90.
411
412
413
24. Morales, D.R.; Morris, A.D.; Annu. Rev. Med. 2015, 66, 17–29.
25. Yu, M.; Li, R.; Zhang, J. Biochem. Biophys. Res. Commun. 2016,
45. Seahorse. Glycolysis Stress Test. Agilent. November 2018.
ysis_Stress_Test_Kit_User_Guide.pdf
46. Seahorse. Mito Stress Test. Agilent. November 2018.
Mito_Stress_Test_Kit_User_Guide.pdf.
471, 639–645.
26. Pestell, R. G. & Rizvanov, A. A. Oncotarget, 2015, 6, 2587–2588.
414
415
27. Adamczyk-Woźniak, A.; Borys, K. M.; Sporzyński, A. Chem. Rev.
416
2015, 115, 5224-5247.
417
418
419
420
421
28. Adamczyk-Woźniak, A.; Cyrański M.K.; Zubrowska, A.;
Sporzyński, A.; J. Organomet. Chem. 2009, 694, 3533-3541.
29. Mereddy, G. R.; Chakradhar, A.; Rutkoski, R. M.; Jonnalagadda,
S. C. J. Organomet. Chem. 2018, 865, 12-22.
47. Seahorse XFe96® based mitochondrial and glycolysis stress
tests: 20,000 cells per well were seeded in a Seahorse XF 96-well
microplate and incubated 18-24 hours at 37⁰C at 5% CO2. For MST,
cells were treated with test compounds, followed by the addition of
oligomycin (ATP synthase inhibitor), FCCP (proton uncoupler),
and rotenone+antimycin A (mitochondrial complex I and III
inhibitors, respectively), at regular time intervals. For GST, the cells
were treated with test compounds, followed by the addition of
glucose (glycolysis initiator), oligomycin (ATP synthase inhibitor)
and 2-deoxyglucose (glycolysis inhibitor) at regular time intervals.
OCR and ECAR were recorded in real-time for MST and GST,
30. Li, X.; Plattner, J. J.; Hernandez, V.; Ding, C. Z.; Wu, W.; Yang,
422
423
Y.; Xu, M. Tetrahedron Lett. 2011, 52, 4924-4926.
31. Xia, Y.; Cao, K.; Zhou, Y.; Alley, M. R. K.; Rock, F.; Mohan, M.;
424
Meewan, M.; Baker, S. J.; Lux, S.; Ding, C. Z.; Jia, G.; Kully, M.;
425
426
Plattner, J. J. Bioorg. Med. Chem. Lett. 2011, 21, 2533-2536.
32. Li, X.; Zhang, S.; Zhang, Y-K.; Liu, Y.; Ding, C. Z.; Zhou, Y.;
427
Plattner, J. J.; Baker, S. J.; Bu, W.; Liu, L.; Kazmierski, W. M.;
428
Duan, M.; Grimes, R. M.; Wright, L. L.; Smith, G. K.; Jarvest, R.
429
L.; Ji, J-J.; Cooper, J. P.; Tallant, M. D.; Crosby, R. M.; Creech, K.;
430
respectively, using a
Seahorse XFe96®analyzer (Agilent).
Glycolytic and mitochondrial parameters were calculated using the
Wave 2.4.0 software (Agilent). Statistical Analysis: Statistics were
computed using GraphPad Prism version 7.0. Repeated measures
Ni, Z-J; Zou, W.; Wright, J. Bioorg. Med. Chem. Lett. 2011, 21,
431
432
433
2048-2054.
7